First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.
Solid Tumor, Adult
DRUG: EOS100850|DRUG: Pembrolizumab|DRUG: Chemotherapy
Incidence of Dose-Limiting Toxicities (DLTs) in patients with advanced solid tumors receiving EOS100850, To define the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D) of EOS100850 in patients receiving EOS100850, During the DLT evaluation period that is cycle 1 (each cycle is 3 or 4 weeks)|Incidence and severity of AEs in patients receiving EOS100850, To assess safety and tolerability as measured by incidence and severity of AEs, Up to 30 months
Plasma concentration of EOS100850 vs. time profiles, Determined by inspection of the concentration-time profile, Up to 30 months|Maximum observed serum concentration (Cmax), Determined by inspection of the concentration-time profile, Up to 30 months|Time of maximum observed concentration (Tmax), Determined by inspection of the concentration-time profile, Up to 30 months|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)], Determined by inspection of the concentration-time profile, Up to 30 months|Plasma concentration half-life (T-HALF), Determined by inspection of the concentration-time profile, Up to 30 months|Overall response rate per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1, Assessment of preliminary efficacy of EOS100850, Up to 30 months
Multicenter, open-label, dose-escalation Phase I/Ib clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of EOS100850 (Inupadenant) as a Single Agent and in Combination with Pembrolizumab and/or Chemotherapy in Participants with Advanced Cancers.